©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Jun 27, 2025; 17(6): 106361
Published online Jun 27, 2025. doi: 10.4240/wjgs.v17.i6.106361
Published online Jun 27, 2025. doi: 10.4240/wjgs.v17.i6.106361
Efficacy and safety of sintilimab combined with nab-paclitaxel plus S-1 for neoadjuvant treatment of locally advanced gastric cancer
Qiu-Xian Chen, Yong-Bin Zhang, Wei-Ming Zeng, Chen-Bin Lv, Ming-Qiao Lian, Rong-Jie Huang, Ming-Jie Lian, Wei-Long Lian, Qian-Hui Xu, Yu-Qin Sun, Li-Sheng Cai, Department of General Surgery, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou 363000, Fujian Province, China
Yi-Chen Cai, College of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing 211816, Jiangsu Province, China
Co-first authors: Qiu-Xian Chen and Yong-Bin Zhang.
Co-corresponding authors: Yu-Qin Sun and Li-Sheng Cai.
Author contributions: Chen QX, Zhang YB, Sun YQ, and Cai LS designed this research study; Chen QX and Zhang YB contributed equally to this article, they are the co-first authors of this manuscript; Chen QX, Zhang YB, and Zeng WM were responsible for the acquisition, analysis, and interpretation of data; Chen QX, Xu HQ, and Zhang YB were in charge of drafting the manuscript; Lv CB, Lian MQ, Lian MJ, Lian WL, and Huang RJ were responsible for the statistical analysis of the data; Chen QX, Cai YC, and Sun YQ provided administrative support, technical support, or material support; Sun YQ and Cai LS contributed equally to this article, they are the co-corresponding authors of this manuscript; and all authors thoroughly reviewed and endorsed the final manuscript.
Supported by the Wu Jieping Medical Fund, No. 320.6750.2022-09-14; and the Climbing Fund of PhD Workstation, Zhangzhou Affiliated Hospital of Fujian Medical University, No. PDB202412.
Institutional review board statement: This study was approved by the Medical Ethics Committee of Zhangzhou Affiliated Hospital of Fujian Medical University, approval No. 2023KYB373.
Informed consent statement: Informed consent to be included in the study, or the equivalent, was obtained from all patients.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Corresponding author: Li-Sheng Cai, Chief Physician, Department of General Surgery, Zhangzhou Affiliated Hospital of Fujian Medical University, No. 59 West Shengli Road, Zhangzhou 363000, Fujian Province, China. wxccls2024@163.com
Received: February 25, 2025
Revised: March 28, 2025
Accepted: May 13, 2025
Published online: June 27, 2025
Processing time: 94 Days and 18 Hours
Revised: March 28, 2025
Accepted: May 13, 2025
Published online: June 27, 2025
Processing time: 94 Days and 18 Hours
Core Tip
Core Tip: This study investigated sintilimab (an immune checkpoint inhibitor) plus nab-paclitaxel and S-1 as neoadjuvant therapy for locally advanced gastric cancer. The combination significantly improved pathological complete response and major pathological response rates, while also demonstrating superior 2-year disease-free survival compared to chemotherapy alone, without additional safety concerns. These findings support its potential as an effective preoperative treatment strategy for locally advanced gastric cancer.